



PATIENTS OLDER THAN 
SIXTY YEARS 
Advanced age has traditionally been a contraindication to cardiac trans- 
plantation. We have, however, offered cardiac transplantation to patients 
older than 60 years with end-stage heart failure if they were otherwise 
acceptable candidates. From 1985 to 1994, 527 patients underwent cardiac 
transplantation. Among these patients, 101 were older than 60 years at 
transplantation. The mean follow-up of this group is 6 years. Patients older 
than 60 years had significantly fewer rejection episodes per patient than 
those who were younger than 60 years at transplantation (1.9 __ 1.3 vs 2.6 - 
1.8, p = 0.009). No difference in the number of infectious complications per 
patient was detected between the two groups. Both short-term and long- 
term survival after transplantation were significantly lower for patients 
who were older than 60 years at transplantation than for younger 
patients (p < 0.05). The 6-year actuarial survival after transplantation 
for patients older than 60 years was 54% compared with 72% for patients 
younger than 60 years at transplantation (p < 0.05). Patients older than 
60 years at transplantation were more likely to die of infectious 
complications or malignant disease after transplantation (p < 0.05). We 
believe caution is warranted in offering cardiac transplantation to 
patients older than 60 years. This group of patients should be carefully 
observed for the development of potentially life-threatening infectious 
complications or new malignant tumors after transplantation. (J TnO- 
RAC CARDIOVASC SURG 1996;111:423-8) 
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I n the 1960s and 1970s, cardiac transplantation was usually restricted to patients younger than 50 years 
of age. 1 In the 1980s, particularly after the introduc- 
tion of cyclosporine, the likelihood of survival after 
cardiac transplantation progressively increased. As 
survival improved, criteria for candidacy became 
less restrictive. The amended criteria included a 
progressive relaxation of the upper age limit for 
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recipients, ultimately including patients older than 
60 years in many cardiac transplant centers. Support 
for relaxation of the upper age limit came from 
several cardiac transplant programs, which reported 
equivalent 1-year survivals for patients older than 60 
years of age. 2-6 In the Utah Transplant Affiliated 
Hospitals (UTAH) Cardiac Transplant Program, 
we have offered cardiac transplantation to pa- 
tients older than 60 years with end-stage heart 
failure if they were otherwise acceptable candi- 
dates for transplantation. However, because the 
availability of donor organs for cardiac transplan- 
tation is limited, a long-term assessment of the 
results of cardiac transplantation i  patients older 
than 60 years should be made, examining whether 
the durable function from each donor heart is 
being realized when the transplant recipient is 
older than 60 years. This report examines the 
long-term results of cardiac transplantation in 
patients older than 60 years. 
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The criteria for eligibility as a cardiac transplant recip- 
ient in the UTAH Cardiac Transplant Program include 
(1) severe class IV cardiac dysfunction unremedial to 
surgical treatment other than cardiac replacement, (2) 
limited life expectancy, with 1-year mortality estimated to 
be greater than 50%, (3) physiologic age less than 65 
years, with an absolute upper limit for chronologic age of 
65 years, (4) no systemic illness other than abnormalities 
related to heart failure, (5) emotional stability, and (6) 
strong family support system. Exclusion criteria include 
(1) severe pulmonary hypertension (pulmonary vascular 
resistance greater than 6 Wood units with inability of 
nitroprusside infusion to reduce resistance to less than 4 
Wood units or inability to reduce pulmonary artery sys- 
tolic pressure below 60 mm Hg), (2) severe irreversible 
hepatic, renal or pulmonary disease, (3) active systemic or 
pulmonary infection, (4) recent pulmonary infarction, (5) 
history of uncontrollable hypertension, defined as blood 
pressure consistently greater than 160/100 mm Hg with 
medical therapy, (6) uncorrectable peripheral vascular 
disease, (7) active peptic ulcer disease, and (8) history of 
substance abuse (including alcohol) or behavior problem 
that would interfere with medical compliance. 
Carotid duplex studies, pulmonary function tests, chest 
x-ray films, arterial blood gases, resting multiple gated 
acquisition scan, echocardiogram, cardiac atheterization, 
purified protein derivative skin test, and dental consults 
are obtained on all potential recipients. Colonoscopy is
performed on all potential recipients older than 50 years. 
Orthotopic ardiac transplants were performed in all 
patients. No effort was made to match older or less than 
ideal donor hearts to older recipients. All recipient pa- 
tients received antibiotic prophylaxis with cefuroxime 
given at least I/2 hour before the operation. Antibiotics 
were added to the pump prime and were administered for 
48 hours after the operation. 
Early rejection prophylaxis was based on murine mono- 
clonal CD3 antibody (OKT3). Our immunosuppressive 
protocol involves a 14-day course of OKT3 beginning with 
a dose during the operation at the time of the pulmonary 
artery anastomosis. OKT3 levels and CD3 lymphocyte 
counts are monitored daily for 14 days. Cyclosporine 
administration is begun on the third or fourth postopera- 
tive day at an oral dosage of 6 mg/kg per day and is 
adjusted to a target trough level of 150 to 200 ng/ml. 
Azathioprine (2 to 4 mg/kg) is administered before the 
operation, and the postoperative dosage is adjusted to 
maintain the white blood cell count between 4 and 6 × 
109/L (4000 and 6000 leukocytes/ml). Methylprednisolone 
is administered during the operation (500 mg intravenous- 
ly). Corticosteroids (prednisone or equivalent) are then 
administered at a dose of 0.25 mg/kg per day until the 
completion of the OKT3 course, when the dosage is 
increased to 1 mg/kg per day for 7 days. 
Average doses of cyclosporine and azathioprine were 
determined for each patient and expressed as milligrams 
per square meter of body surface area per day. Steroid 
dosing was calculated as prednisone quivalents, that is, 1 
mg of prednisone = 0.8 mg of methylprednisolone = 4mg 
of hydrocortisone, and included steroids administered to 
the patient at the time of the operation. Cumulative 
steroid dosing, expressed as milligrams per kilogram, was 
determined at each posttransplantation year. 
Patients routinely underwent endomyocardial biopsy 
weekly for 6 to 8 weeks after transplantation. The fre- 
quency of biopsy was then decreased in accordance with 
the status of cardiac rejection. Rejection was treated with 
high-dose methylprednisolone or prednisone, with or 
without antithymocyte globulin, OKT3, or rabbit antilym- 
phoblast globulin, followed by gradually decreasing doses 
of prednisone. After the prophylactic use of prednisone, 
or after its use in the treatment of rejection, prednisone 
was gradually decreased and discontinued unless cardiac 
rejection recurred. The process of prednisone dosage 
reduction and discontinuation was repeatedly attempted 
until three rejection episodes within a 4-month period had 
occurred in a given recipient, at which time the pred- 
nisone dosage was maintained at the lowest level neces- 
sary to prevent recurrent rejection (5 to 20 mg per day). 
Rejection was diagnosed from histologic studies of the 
endomyocardial biopsy specimens. Biopsy specimens were 
graded by the consensus of three cardiac pathologists. 
Rejection severity was grade 0 to 4 according to the 
International Society for Heart and Lung Transplantation 
grading system] Grade 2 was managed with an increase in 
oral steroids. Intravenous bolus steroid therapy was given 
for grade 3A rejection. Patients with grade 3B rejection 
also received cytolytic therapy as indicated. Grade 4 
rejection was managed with both cytolytic therapy and 
intravenous steroids. 
The number of serious infections, defined as infections 
necessitating intravenous antibiotics, was determined for 
each patient. The infections were categorized according to 
originating site in all instances. Evidence of prior cyto- 
megalovirus infection in either donor or recipient was 
treated with prophylactic gancyclovir. 
Data regarding age at transplantation, number of male 
and female patients, indication for transplantation, um- 
ber of patients whose condition is designated status 1, 
length of time on the waiting list, donor heart ischemic 
time, postoperative immunosuppressive r gimens and 
dosages, number and severity of rejection episodes, num- 
ber and site of episodes of infection, cause of death, and 
survival are continuously updated for each transplant 
recipient in the UTAH Cardiac Transplant Program as 
part of our ongoing patient database. This information 
from the database forms the basis for this report. 
Survival curves for patients younger than 60 years and 
older than 60 years at transplantation were established, 
with mortality as the main outcome variable, by means of 
the Kaplan-Meier method and compared by the Wilcoxon 
and log-rank tests. The X 2 test was used to compare 
qualitative demographic and cause of death data. The t 
test was used to compare quantitative data between the 
two groups, reported as the mean -+ standard eviation. 
Results 
From 1985 to 1994, 527 patients underwent car- 
diac transplantation, of  whom 101 were older than 
60 years of age at transplantation. The mean fol- 
low-up of this group of patients is 6 years, with the 
longest follow-up being 9 years. 
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Table I. Comparison of recipient characteristics 
Age > 60 yr Age < 60 yr 
P 
No. % No. % Value 
Male 92 91 357 84 NS 
Ischemic ardiomyopathy 63 62 213 50 NS 
Status 1 44 44 179 42 NS 
NS, Not significant. 
Table II. Comparison of recipient characteristics 
P 
Age > 60 yr Age < 60 yr Value 
Time on waiting list (days) 80 _+ 117 74 _+ 82 NS 
Donor heart ischemic 157 +- 62 170 _+ 60 NS 
time (rain) 
Cumulative steroids at 12,616 -+ 32,049 9694 +_ 5468 NS 
1 yr (mg/kg) 
NS, Not significant 
Patients older than 60 years had significantly 
fewer rejection episodes per patient han those who 
were younger than 60 years at transplantation (1.9 +_ 
1.3 vs 2.6 +_ 1.8,p = 0.009). However, no significant 
difference was noted between the two groups as to 
the number of male versus female patients, number 
of patients in status 1 condition, or the incidence of 
ischemic, idiopathic, or viral cardiomyopathy as the 
indication for transplantation (Table I). The two 
groups also did not differ with regard to length of 
time on the waiting list before transplantation, do- 
nor heart ischemic time, or peak or cumulative 
doses of cyclosporine, azathioprine (Imuran), ste- 
roids, or OKT3 (Table II). No difference was de- 
tected in the number of infectious complications per 
patient between the two groups. Older and younger 
patients did not significantly differ in their ability to 
be weaned from steroids after transplantation. The 
prevalence of infectious complications did not vary 
with the steroid dosage after the operation. 
Both the short-term and long-term survivals after 
transplantation were significantly poorer for pa- 
tients who were older than the age of 60 years at 
transplantation than for younger patients (p < 0.05) 
(Fig. 1). Analysis of the actuarial survival curves for 
the two groups demonstrates divergence of the 
curves beginning 6 months after transplantation. 
The difference between the curves becomes more 
pronounced at I year with progressive divergence of 
the curves thereafter. The 6-year actuarial survival 
after transplantation for patients older than 60 years 
was 54% compared with 72% for patients operated 
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Fig. 1. Actuarial survival curves after transplantation for
patients younger than 60 years and older than 60 years at 
cardiac transplantation. 
on when younger than 60 years (p < 0.05). Although 
no statistically significant difference between the two 
groups was detected with regard to the number of 
infectious complications per patient, patients older 
than 60 years were more likely to die of an infectious 
complication after transplantation (p -< 0.003). 
These fatal infectious complications included gram- 
negative sepsis (n = 7), Aspergillus (n = 6), Candida 
(n = 2), Nocardia (n = 1), mucormyeosis (n = 1), 
and hepatitis C (n = 1). There was no difference in 
the specific causes of fatal infectious complications 
when comparing the two age groups. 
Patients older than 60 years were also more likely 
to die of malignant disease after transplantation 
(p = 0.015). Among these patients, the fatal malig- 
nancies were lymphoma (n = 3), leukemia (n = 1), 
carcinoma of the lung (n = 2), and carcinoma of the 
esophagus (n = 1). The overall prevalence of 
posttransplantation lymphoproliferative disorders 
in our program is 2%. No difference in the specific 
types of malignant disease surfaced when the two 
age groups were compared. Patients with a post- 
transplantation lymphoproliferative disorder were 
initially treated with a reduction in immunosup- 
pression. If this therapy was unsuccessful, they 
began chemotherapy. 
The two groups did not otherwise differ with 
regard to the prevalence of acute or chronic rejec- 
tion or accelerated coronary atherosclerosis a the 
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Table III. Comparison of causes of death between 
groups 
Age > 60 yr Age < 60 yr 
Cause of death No. % No. % p Value 
Infection 18 18 34 7 -<0.003 
Malignancy 7 7 8 2 0.015 
Chronic rejection 8 8 30 7 NS 
Acute rejection 2 2 12 3 NS 
Gastrointestinal 12 3 NS 
Operative 1 1 9 2 NS 
Renal 4 1 NS 
Pulmonary 3 1 NS 
Other 1 1 6 1 NS 
cause of death. No significant difference was noted 
between the two groups as to the prevalence of 
gastrointestinal, renal, pulmonary, neurologic, or 
other complications as the cause of death (Table 
Ill). 
Discussion 
As survival after cardiac transplantation im- 
proved, criteria, including age, gradually were re- 
laxed. Cited in support of such policy changes were 
the results from several centers indicating that sur- 
vivals were not significantly worse in patients older 
than 60 years. 2-6 These reports, however, were lim- 
ited by small numbers of patients and short-term 
follow-ups. Long-term survival and functional re- 
sults become more relevant when the best use of a 
limited supply of cardiac donors is Considered. 
Our data show a significantly reduced short-term 
and long-term survival in transplant recipients older 
than 60 years. The cardiac recipient older than 60 
years has, in our experience, an increased likelihood 
of death caused by infection and malignancy. 
Our observations suggest that physiologic hanges 
take place beyond 60 years of age, which may 
significantly affect long-term survivals after cardiac 
transplantation. Older patients have decreased im- 
mune responsiveness and T-cell function and, as a 
56 group, may require less immunosuppression. ' Our 
data and those of others confirm that patients older 
than 60 years have fewer rejection episodes per 
patient han recipients younger than 60 years. 2' 3, 6 
On the other hand, patients older than 60 years are 
more likely to die of an infectious complication or 
malignant disease after transplantation. Perhaps a 
decline in immune responsiveness resulting in fewer 
rejection episodes in patients older than 60 years 
may also make them more susceptible to fatal 
infectious complications or malignant disease after 
transplantation. An alternative, but not mutually 
exclusive, hypothesis i that this age group may be 
susceptible to relative over-immunosuppression. It 
seems unlikely that differences in mortality between 
the two groups can be ascribed to latent pathophys- 
iology in the older patients before transplantation, 
because older patients were subjected to the same, 
or even more rigorous, selection criteria as the 
younger patients. Moreover, we did not observe any 
increase in death from other causes typically seen in 
older patients, such as renal, cerebrovascular, pul- 
monary, or gastrointestinal disease (Table III). 
This information is important when future guide- 
lines are considered for selection of patients older 
than 60 years for cardiac transplantation. Improve- 
ments in immunosuppression a d other aspects of 
management have achieved acceptable short-term 
survivals in a variety of potential recipients at high 
risk, including patients older than 60 years. Relax- 
ation of criteria or candidacy and hence expansion 
of the recipient pool, however, stresses an already 
inadequate donor supply. Careful review of the 
likely long-term outcome of a potential recipient 
should be undertaken to ensure that donor hearts 
will most effectively benefit the entire group of 
potential transplant recipients. At present, we re- 
main highly selective in accepting patients older 
than 60 years as potential cardiac transplant recipi- 
ents. The presence of any of the exclusion criteria 
discussed herein contraindicates transplantation. 
Once these patients are accepted, however, we do 
not penalize patients older than 60 years or assign 
them a lower priority score on the basis of their age, 
nor do we attempt o match older donor hearts to 
older recipients. 
Analysis of our long-term actuarial survival after 
cardiac transplantation leads us to speculate that 
cardiac transplantation may be of limited utility for 
the management of end-stage heart failure in pa- 
tients older than 60 years, unless improvements in, 
or tailoring of, immunosuppressive regimens reduce 
the prevalence of late infectious and malignant 
complications. If this can be accomplished, while 
maintaining an acceptable risk of rejection, then 
improvement in long-term survival may be possible 
in the patient older than 60 years. 
Nonetheless, we maintain that cardiac transplan- 
tation, when offered to patients older than 60 years, 
must be prefaced by strict criteria for candidacy and 
followed by rigorous urveillance to detect and treat 
potentially fatal infectious complications and malig- 
nant diseases. 
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Discussion 
Dr. Robert C. Robbins (Stanford, Calif.). Dr. Bull's data 
are important o consider in this economically efficient 
environment. Several centers, including the Utah group, 
have previously reported that the 1-year survival for older 
cardiac transplant recipients was equivalent to survival in 
younger patients. This is the first report to describe the 
intermediate-term results for older cardiac recipients. The 
6-year actuarial survival for patients older than 60 years is 
clearly lower than for patients younger than 60 years, with 
the actuarial curves beginning to diverge 1 year after 
transplantation. The actuarial su/'vival of 35 cardiac trans- 
plant recipients older than 60 years operated on at 
Stanford over the past 10 years was the same as the 
survival of younger patients during this same period. Of 
the 10 deaths in these older patients, two were the result 
of infection and one the result of a nonlymphoid malig- 
nancy. One would expect hat actuarial survival decreases 
with age, but this paper focuses on malignancy and 
infection as the primary causes of death. 
Serious infection is defined as an episode requiring 
intravenous antibiotics. There is no information detailing 
the types of infections observed. Specifically, I would be 
interested in the incidence of bacterial, viral, and fungal 
infections. Was cytomegalovirus prophylaxis used as a 
routine and, if so, for which subsets of patients? 
The incidence of malignancy increases with age and the 
cancer-related deaths observed in the older patients may 
be explained on this basis. Because induction therapy with 
OKT3 was used, it would be interesting to see a more 
detailed escription of the types of cancer that developed 
in these patients. What was the prevalence of lymphopro- 
liferative disorders and how were these managed? Was 
colonoscopy performed as part of the preoperative eval- 
uation in the older patients? 
The older patients had fewer rejection episodes than 
the younger recipients. It would be helpful to see a 
stratification of the grades of rejection for each group, 
which grades of rejection were treated, and the correla- 
tion of treatment with the development of infection and 
malignancy. 
Because the older patients have less rejection, are we all 
over immunosuppressing this population? What percent- 
age of patients in each group stopped receiving steroids? 
Would it be reasonable to eliminate induction therapy in 
this group of less immunocompetent patients? 
The concept hat older patients may be better served 
with the implantation of a left ventricular assist device is 
attractive; however, this approach should be used with 
caution because the survival of older patients receiving 
left ventricular assist device support is less than that of 
younger patients. The recent effort by John Wallwork and 
associates in Cambridge to use the Novacor left ventricu- 
lar assist system as an alternative to transplantation for 
older patients will be extremely useful in providing data 
concerning this novel treatment. 
Dr. Bull. We have been aggressive about performing 
transplantation in recipients older than 60 years. Nearly 
20% of our transplant population has been older than 60 
years. This compares with 11% in the Stanford experi- 
ence. Inasmuch as older patients were subjected to the 
same or more rigorous candidacy criteria as younger 
patients, I do not believe that our patient selection is the 
explanation for the less favorable long-term survival in 
older patients. This is evidenced by the lack of a significant 
difference in the incidence of renal, pulmonary, gastroin- 
testinal, and neurologic omplications between the two 
groups. 
In 1987, we published ata regarding the age-associated 
decline in cardiac allograft rejection. This paper had a 
small number of patients with short-term follow-up. The 
conclusion of the paper was that survival was equal 
between older and younger patients at 1-year follow-up. 
We did not start o see a difference in survival until we had 
a larger number of patients whom we had followed up for 
a longer period after transplantation. 
With regard to infection, a number of recipients older 
than 60 year s died 6 to 12 months after transplantation f 
fungal infections, particularly Aspergillus. After 1 to 2 
years, a number of older recipients died of gram-negative 
sepsis. We are unable, however, to make statistical con- 
clusions regarding the specific cause of infection and 
mortality. The only conclusion we are able to draw at this 
time is that mortality from infection in patients older than 
60 years is greater than that in younger patients. Our 
purpose with this study was not to delineate the specific 
cause of infection or malignancy but rather to compare 
the overall survival of our transplant population on the 
basis of age. We believe such an analysis is helpful to 
determine the best use of donor hearts, which are in 
limited supply for both older and younger ecipients. 
Colonoscopy is part of our routine screening program 
in potential recipients older than 50 years. Lymphopro- 
liferative disorders were the leading cause of malig- 
nancy in our recipients older than 60 years. Our first- 
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line of treatment for patients with a posttransplantation 
lymphoproliferative disorder is to reduce their immu- 
nosuppression. If this is unsuccessful, the patients begin 
chemotherapy. After lymphoproliferative disorders, the 
most common types of malignancy were solid organ 
tumors. 
We use the International Society for Heart and Lung 
Transplantation grading system for rejection. Patients 
with grade 2 rejection are treated with an increase in oral 
steroids. Patients with grade 3A rejection are treated with 
intravenous bolus steroid therapy. Patients with grade 3B 
rejection may also receive cytolytic therapy. Patients with 
grade 4 rejection are treated with both cytolytic therapy 
and intravenous steroids. 
It was not possible from our analysis to assess whether 
the older patients were excessively immunosuppressed. 
We have looked at subsets of T cells in older patients. As 
you know, T effector cell-mediated immunity is the pri- 
mary arm of the immune system involved in allograft 
rejection. We have not been able to determine any 
numeric differences in subpopulations of T cells between 
older and younger patients. The increased mortality from 
infection and malignancy, however, may be due to immu- 
nosenescence. This term describes the decreased mito- 
genic response to an antigenic stimulus with aging, result- 
ing in a functional decrease in T-cell activity. We still have 
much to learn about the changes in the immune system 
with aging. 
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